As reported in the
IP Update, Text of CETA released the text of CETA was released on September 26,
2014. As reported in that article, CETA, Chapter 22 in particular, includes provisions
specifically impacting pharmaceuticals/biologics in three areas:
(i) patent term restoration (PTR); (ii) innovator right of appeal
under the Patented Medicines (Notice of Compliance)
Regulations; and (iii) data protection. See also our
November 14, 2013 article: Comprehensive Economic and Trade
Agreement between Canada and Europe to result in greater protection
for pharmaceutical patentees.
This article provides more details regarding the patent term
restoration provision, Article 9.2, entitled Sui Generis [Latin for
"unique"] protection for Pharmaceuticals. Broadly, this
form of protection effectively extends patent term to account for
marketing delays resulting from the time required to obtain
regulatory approval. While the EU has had patent term restoration -
granted by way of sup